Plant Exosome Market Report: Trends, Forecast and Competitive Analysis to 2035

Plant Exosome Market

The future of the global plant exosome market looks promising with opportunities in the pharmaceutical & health product, skin care product, and scientific research markets. The global plant exosome market is expected to reach an estimated $563.1 million by 2035 from $134.4 million in 2027 with a CAGR of 20.1% from 2027 to 2035. The major drivers for this market are the increasing use in drug delivery research, the rising demand for natural cosmetic ingredients, and the growing investments in plant based biotechnology.

• Lucintel forecasts that, within the type category, ginger tissue exosomes is expected to witness the highest growth over the forecast period due to high yield of bioactive compounds from ginger tissue exosomes.
• Within the application category, skin care products is expected to witness the highest growth over the forecast period due to increased request for clean-label plant-based ingredients in skin care.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to growing production and manufacturing of cosmetics and the commercial sourcing of raw materials.

Emerging Trends in Plant Exosome Market

Between the years 2025 to 2027, the market for plant exosomes will shift from experimental and subjective skincare and nutraceutical products to more validated and reproducible products. Lucintel's report reflects and supports trends observed in the marketplace. Other suppliers in the market are investing in partnering with research organizations to develop botanical products for drug delivery systems.

• Standardization: There are several publications from the market discussing the requirements of establishing consistency in batch-to-batch exosome products, and the role of marker proteins and RNA. In the absence of such standards, the potency and other identity tests may limit the uses of plant exosome products to premium skincare and nutraceutical products.
• Clinical Validation: In 2025 to 2027, the focus of the product development was to set endpoints to support product claims, thereby separating skincare products into cosmetics and drugs. Suppliers are investing in clinical research to support their product claims.
• Scalable Manufacturing: Suppliers have developed and scaled up their processes to manufacture plant-based exosomes in large batches; closed systems for extraction and filtration and Cold Chain systems are now in use. Contract manufacturing organizations are now offering plant-based exosome products.
• Sustainability: The traceability and resource disclosure requirements for packaging and ingredients by 2025 will likely prompt brands to consider various sources for extracellular vesicles, of which plant-based sources are renewable. With continued focus on lowering the environmental footprint of products, plant-based extracellular vesicles may be incorporated in the future to perform functions such as encapsulation and transport.
• Drug-delivery Integration: Publications released through 2025 explore the use of plant extracellular vesicles for drug delivery. Topical products are the primary focus of the research, but collaborations planned for 2026 and beyond will consider other product forms. The use of plant extracellular vesicles for drug delivery may enable the creation of pharmaceuticals and other functional foods.

Competing for a position in the plant extracellular vesicle market will focus less on innovating and more on repeatability. Long-term customer relationships will be the result of strong regulatory and compliance strategies. Trust in a company's ability to control the identity and purity of a product will likely come from the publication of human clinical data and the establishment of regulation-compliant claims. Demand for cosmetics will likely fund the initial, or early, stages of product development. Pharmaceutical partnerships will likely drive the development of the company and focus on higher-value products.

Recent Developments in the Plant Exosome Market

Plant-based exosomes are expected to gain commercial traction between 2025 and 2027 with further research by cosmetic and biotech firms and advancements in exosome-based delivery systems. According to Lucintel, there is increased focus on plant-based extracellular vesicles due to ethical and supply concerns associated with animal-based extracellular vesicles. Regulatory frameworks governing extracellular vesicles are yet to be established.

• Commercial Product Launches: In January 2025, a South Korean skincare company launched a serum containing plant-based extracellular vesicles. The launch created product differentiation and market-pull for similar products.
• Strategic Partnering: In April 2025, a biotech firm entered into a partnership with a contract manufacturing organization to scale a 2,000 liter plant-based cell culture. This partnership improved the consistency of the plant cell culture and reduced dependency on lab-scale production.
• Technology Improvement: In June 2025, researchers reported the use of plant-based exosomes for drug delivery. Improvements in skin permeability and exosome loading may alter the exosome market from an "ingredient" to a "platform" market.
• Progress in Regulatory Frameworks: In September 2025, a U.S. firm filed a Cosmetic Product Safety Notification for plant-based exosomes to demonstrate their safety for use in cosmetics. The filing facilitated market entry of safe, bona fide plant-based exosome products.
• Major Expansion: An ingredients company out of Europe announced in February 2026 plans to build a 10,000 square foot controlled environment facility to produce botanical vesicles. More production capacity is expected to help the company win larger contracts in the cosmetics market and decrease the lead time on its orders. The company is reportedly continuing efforts to optimize the purification of botanical compounds to improve the economics of its products.

In the skincare market, the barrier to entry for new companies is lower due to less stringent regulations and a larger customer base compared to the medical market. New competitors should evaluate the medical market, as there is a greater opportunity for profit, but additional hurdles including the completion of clinical studies.

In the coming years, the most successful companies in the market are expected to be vertically integrated to perform all critical functions (cultivation, extraction, testing and formulation) to improve profit margins. Buyers will stop accepting commodity products and will require manufacturers to prove their products contain active compounds.

Strategic Growth Opportunities in the Plant Exosome Market

2026 is expected to be a milestone year as the industry progresses from research and development to commercial growth. Increasing concern for cell-based delivery, cosmetic differentiation, and use of non-animal ingredients and other similar trends foster investments. In the opinion of Lucintel, commercially successful offerings would require disciplined attention to standardization and regulation.

• Advanced Skincare Actives: In vitro studies and formulation development focused on extracellular vesicles derived from plants are expected to gain traction. Commercial opportunity would be enhanced with the development of standardized methods and protocols.
• Research Tools: Both the academic and the biotechnology industries are expected to drive demand for exosome-based transport systems. Increased emphasis on the use of standardized methods and reproducibility is expected to foster demand.
• Bios Stimulants: Plant bio stimulants, including delivery systems based on exosomes, have the potential to improve crop health and reduce the use of synthetic crop inputs. The FAO report (June 2025), estimated that 4.2 billion tons of crop inputs were used in agricultural activities across the world.
• Animal Health: CFMs as wound care and anti-inflammatory agents are both commercially and societally relevant. The APPA projects U.S. spending on pets and pet care reached $152B in 2024, providing opportunity for early stage products in veterinary medicine.
• Contract Manufacturing: The cell culture, purification, and Characterization and documentation services offered by CMOs enable them to bridge the last gaps for clients and offer commercial services. In 2025, surveyed CMOs identified >20 attributes of extracellular vesicles for characterization. Commercial services are increasingly outsourced.

There is untapped potential to patent and commercialize biomedical innovations. Validated suppliers of biologics will find the most lucrative opportunities in premium skincare and cosmetics. The strongest, longer term opportunities are in prescription drugs and other therapeutic interventions. Life science tools and other biomedical innovations will remain regulated and controlled for some time; however, the most promising technologies will engage and partner with other regulated, commercial industries.

Plant Exosome Market Drivers and Challenges

The plant exosome market is taking shape due to the rapid-fire nature of technology and industry advancements, increasing demand from the field of cosmetic medicine and allied industries, increasing investments, and relaxing regulations. Sponsored by research, increasing investments are expected to catalyze improvements in the market in the coming years.

The factors responsible for driving this market include :

• Increasing Demand for Regenerative Medicine: The use of exosomes in the field of regenerative medicine is gaining traction as exosomes are believed to promote cellular repair and regulate inflammation. A sustained interest in less invasive, regenerative medical solutions is expected to foster continued research and development in the field of plant exosomes. In January 2025, the International Clinical Trials Registry Search Platform listed more than 100 ongoing studies evaluating the potential medical benefits of exosomes.
• Improvements in Technology: There have been advances in isolation and purification of plant exosomes, as well as in molecular profiling and loading of exosomes from plant sources. In 2025, many laboratories combined multiple methods, including nanoparticle tracking, omics, and electrons microscopy, for analyzing the quality of samples. It is expected that within the next 5 years, methods for evaluating and characterizing plant exosomes will be more developed, allowing a greater control over exosome-based products, and ultimately their market introduction.
• Plant Exosomes in Cosmetics: Plant-based exosomes are suitable for topical applications and have potential in skincare and haircare products. Exosome-based cosmetic products are expected to gain popularity in the next 5 years. 2025 saw the launch of a series of exosome-based skincare products in North America and Asia. Most of the products were formulated to address multiple skin concerns. In the future, new products are expected, with focus on advanced and individualized skincare.
• Sustainability and Vegan Exosomes: Exosomes sourced from plant-based systems allow product formulations without use of animal-based systems and provide sustainability, vegan, and other comparable benefits. In addition to the cosmetic industry, plant-based exosomes are expected to gain popularity in other industries, including pharmaceuticals and health and wellness products.
• Potential for Improved Economic Production: Plant materials can be produced, processed and refined in a reproducible and scalable manner. This can result in less expensive production than some complex systems that rely on the use of mammalian cell culture. There has been progress in developing methods that incorporate multiple stages of biomass processing and purification, such as multi-stage filtration and chromatography. The use of improved raw materials, continuous processing, and automation in combination with the methods mentioned above, is expected to reduce costs and enhance the reliability of the exosome supply.

The challenges facing this market include:

• Variability in Regulatory Frameworks: Regulatory agencies have not developed or harmonized international standards and guidelines for the assessment of plant-based exosome products. In 2025, product classifications were often limited to a single jurisdiction. It is anticipated that during the next 3-5 years, variable regulatory requirements will increase the cost of doing business and negatively impact the ability to market products across international borders.
• Standardization and Quality: There are intrinsic variations in composition of exosomes derived from various plant species and other growing and harvesting variables. In 2025, researchers relied on multiple methods to assess batch-to-batch variability. It is expected that during the next 3-5 years, variable exosome product specifications will restrict the ability to support therapeutic applications.
• Weak Clinical Data and High Expenses: The existing body of evidence largely consists of pre-clinical and laboratory studies. Sponsored studies have gradually increased the number of exosome candidates undergoing late-stage human testing; however, as of October 2025, published reports indicated that the overwhelming majority of exosome candidates have not completed advanced clinical trials. In the next several years, exosome therapy is likely to encounter similar challenges. Unless significant data from well-controlled clinical trials are made available, the adoption of exosome therapies is likely to be limited.

The future of the plant-based exosome market looks bright. Growing consumer awareness regarding the use of regenerative, sustainable, and ethical sources in various markets is likely to work in the market's favor. Improving technology and large-scale plant cultivation could increase the market's competitiveness and decrease the cost of production. There are several opportunities to market exosome-based products in the cosmetics industry prior to their introduction in the pharmaceutical market. The market is likely to grow in the same fashion as other fields of biotechnology, with advances being made primarily in the research and high-end, non-pharmaceutical markets.

List of Plant Exosome Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies plant exosome market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the plant exosome market companies profiled in this report include-

• Creative Biostructure
• SBS Genetech
• HansaBioMed
• CD Bioparticles
• Liaoning Runji Biological

Plant Exosome Market by Segment

The study includes a forecast for the global plant exosome market by type, application, and region.

Plant Exosome Market by Type [Value ($M) from 2019 to 2035]:

• Ginger Tissue Exosomes
• Onion Exosomes
• Potato Exosomes
• Seaberries Exosomes
• Garlic Exosomes
• Others

Plant Exosome Market by Application [Value ($M) from 2019 to 2035]:

• Pharmaceuticals & Health Products
• Skin Care Products
• Scientific Research
• Others

Plant Exosome Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Plant Exosome Market

The market for plant-based exosomes is shifting from basic research to development of ingredients and platforms for drug and cosmetic delivery. The 2025-2027 time frame will see investment for refining methods for isolating and characterizing plant-based exosomes. Based on recently published studies by Lucintel, the market is advanced where legal frameworks and standards for manufacturing are in place.

• United States: The FDA has said that exosome products that are drug products require an IND. In February 2025, the FDA stated that exosome products that are drugs and/or biological products cannot be legally marketed. There are universities and biotechnology companies that are developing plant-based extracellular vesicles for delivery of drug products. Other vesicle products, e.g., ginger vesicles, are also being developed for drug delivery. In the near term, the market will favor companies that can develop consistent methods for producing vesicle products.
• China: Plant-based extracellular vesicles are being developed for drug and cosmetic delivery as well as delivery of nucleic acids. In 2025, Chinese researchers reported the laboratory scale synthesis of plant vesicles for the delivery of drug products. Continued support by the Chinese government for research and development of traditional medicines is expected to foster the establishment of vesicle drug product development and manufacturing capabilities.
• Germany: Germany continues to draw extracellular-vesicle research, mainly through university hospitals, Fraunhofer Institutes, and funded biotechnology programs. The European Medicines Agency's (EMA) reflection work on advanced biological products is informing the characterization and quality systems needed to support marketing authorization, and will impact the plant-based extracellular vesicles industry.
• India: Plant-based extracellular and intracellular vesicles are being utilized in biotech and cosmeceutical products. Biotechnology research is also funded by the Government of India. As of April 2025, India's biotech sector reported over 10,000 startups, and will facilitate technology, manufacturing and product partnerships.
• Japan: High-end skincare products containing plant-based extracellular vesicles are being developed. The Ministry of Health, Labor and Welfare of Japan is regulating product claims and the safety of ingredients. Manufacturers are encouraged to utilize validated suppliers and make claims based on performance.

Features of the Global Plant Exosome Market

• Market Size Estimates: plant exosome market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: plant exosome market size by type, application, and region in terms of value ($B).
• Regional Analysis: plant exosome market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the plant exosome market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the plant exosome market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the plant exosome market by type (ginger tissue exosomes, onion exosomes, potato exosomes, seaberries exosomes, garlic exosomes, and others), application (pharmaceuticals & health products, skin care products, scientific research, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?